The DUTCH-ICD study aims to refine risk stratification and improve clinical decision-making regarding implantable cardioverter-defibrillator (ICD) therapy in patients with non-ischemic cardiomyopathy (NICM), in order to select patients at highest risk. This study consists of a randomized controlled trial and a registry.
In this registry, 720 patients will be included with NICM, LVEF<35%, but without fibrosis on Cardiac Magnetic Resonance Imaging (CMR). This registry population will provide a reference perspective for the main trial by specifically including patients without fibrosis.
In parallel, patients with NICM, LVEF <35% and with myocardial fibrosis on CMR will be included into the RCT. Patients in the intervention group will receive ICD implantation in addition to optimal drug therapy (OMT). Patients in the control group will receive OMT only.